Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
Condition: HER2-Negative Breast Cancer Intervention: Drug: Pembrolizumab Sponsors: University of Malaya; Merck Sharp & Dohme (MSD); National University Hospital, Singapore; Clinical Research Malaysia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hospitals | Malaysia Health | Research | Singapore Health | Study